These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 29660756)

  • 41. Impact of palivizumab prophylaxis on respiratory syncytial virus hospitalizations in high risk Alaska Native infants.
    Singleton R; Dooley L; Bruden D; Raelson S; Butler JC
    Pediatr Infect Dis J; 2003 Jun; 22(6):540-5. PubMed ID: 12799511
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Palivizumab for respiratory syncytial virus prophylaxis.
    Sandritter T
    J Pediatr Health Care; 1999; 13(4):191-5; quiz 196-7. PubMed ID: 10690084
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Palivizumab: The Effects of Prophylactic Immunization on the Occurrence of Infections Caused by the Respiratory Syncytial Virus.
    Raguz MJ; Brzica J; Grgic I
    Klin Padiatr; 2017 Sep; 229(5):281-285. PubMed ID: 28946159
    [No Abstract]   [Full Text] [Related]  

  • 44. Palivizumab prophylaxis during nosocomial outbreaks of respiratory syncytial virus in a neonatal intensive care unit: predicting effectiveness with an artificial neural network model.
    Saadah LM; Chedid FD; Sohail MR; Nazzal YM; Al Kaabi MR; Rahmani AY
    Pharmacotherapy; 2014 Mar; 34(3):251-9. PubMed ID: 23897635
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Incidence of respiratory syncytial virus-related hospitalizations in high-risk children: follow-up of a national cohort of infants treated with Palivizumab as RSV prophylaxis.
    Lacaze-Masmonteil T; Rozé JC; Fauroux B;
    Pediatr Pulmonol; 2002 Sep; 34(3):181-8. PubMed ID: 12203846
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Monoclonal antibody for reducing the risk of respiratory syncytial virus infection in children.
    Andabaka T; Nickerson JW; Rojas-Reyes MX; Rueda JD; Bacic Vrca V; Barsic B
    Cochrane Database Syst Rev; 2013 Apr; (4):CD006602. PubMed ID: 23633336
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Palivizumab immunoprophylaxis effectiveness in children with cystic fibrosis.
    Winterstein AG; Eworuke E; Xu D; Schuler P
    Pediatr Pulmonol; 2013 Sep; 48(9):874-84. PubMed ID: 23139089
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Cost-effectiveness of respiratory syncytial virus prophylaxis in various indications.
    Hampp C; Kauf TL; Saidi AS; Winterstein AG
    Arch Pediatr Adolesc Med; 2011 Jun; 165(6):498-505. PubMed ID: 21300647
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Partial palivizumab prophylaxis and increased risk of hospitalization due to respiratory syncytial virus in a Medicaid population: a retrospective cohort analysis.
    Krilov LR; Masaquel AS; Weiner LB; Smith DM; Wade SW; Mahadevia PJ
    BMC Pediatr; 2014 Oct; 14():261. PubMed ID: 25308481
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Respiratory disorders and hospitalization rates during the second RSV season in preterm infants who received palivizumab prophylaxis during their first RSV season.
    Fanos V; Scarcella A; Puddu M; Gallini F; Tuminelli F; Bragetti P; Gallina MR; Quartulli L; Benincori N; Citro G; Via LD; Barera G; DI Luzio Paparatti U; Merolla R; Romano GV; Guida G; Silvestri M; Rossi GA
    J Chemother; 2009 Jun; 21(3):302-10. PubMed ID: 19567351
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Infant respiratory syncytial virus prophylaxis and nasopharyngeal microbiota until 6 years of life: a subanalysis of the MAKI randomised controlled trial.
    Man WH; Scheltema NM; Clerc M; van Houten MA; Nibbelke EE; Achten NB; Arp K; Sanders EAM; Bont LJ; Bogaert D
    Lancet Respir Med; 2020 Oct; 8(10):1022-1031. PubMed ID: 32203712
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Palivizumab prophylaxis, respiratory syncytial virus, and subsequent recurrent wheezing.
    Simoes EA; Groothuis JR; Carbonell-Estrany X; Rieger CH; Mitchell I; Fredrick LM; Kimpen JL;
    J Pediatr; 2007 Jul; 151(1):34-42, 42.e1. PubMed ID: 17586188
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Effectiveness of Palivizumab Against Respiratory Syncytial Virus Hospitalization Among Preterm Infants in a Setting With Year-Round Circulation.
    Yeo KT; Yung CF; Khoo PC; Saffari SE; Sng JSP; How MS; Quek BH
    J Infect Dis; 2021 Jul; 224(2):279-287. PubMed ID: 33274362
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Impact of the 2014 American Academy of Pediatrics recommendation and of the resulting limited financial coverage by the Italian Medicines Agency for palivizumab prophylaxis on the RSV-associated hospitalizations in preterm infants during the 2016-2017 epidemic season: a systematic review of seven Italian reports.
    Cutrera R; Wolfler A; Picone S; Rossi GA; Gualberti G; Merolla R; Del Vecchio A; Villani A; Midulla F; Dotta A
    Ital J Pediatr; 2019 Nov; 45(1):139. PubMed ID: 31706338
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Outcomes of Infants Receiving Palivizumab Prophylaxis for Respiratory Syncytial Virus in Canada and Italy: An International, Prospective Cohort Study.
    Manzoni P; Paes B; Lanctôt KL; Dall'Agnola A; Mitchell I; Calabrese S; Maule M; Girardi E; Harimoto T; Li A
    Pediatr Infect Dis J; 2017 Jan; 36(1):2-8. PubMed ID: 27649365
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Impact of the Updated Guidance for Palivizumab Prophylaxis against Respiratory Syncytial Virus Infection: A Single Center Experience.
    Rajah B; Sánchez PJ; Garcia-Maurino C; Leber A; Ramilo O; Mejias A
    J Pediatr; 2017 Feb; 181():183-188.e1. PubMed ID: 27855996
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A meta-analysis of the effect of antibody therapy for the prevention of severe respiratory syncytial virus infection.
    Morris SK; Dzolganovski B; Beyene J; Sung L
    BMC Infect Dis; 2009 Jul; 9():106. PubMed ID: 19575815
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Comparison of the timing of initial prophylactic palivizumab dosing on hospitalization of neonates for respiratory syncytial virus.
    Ohler KH; Pham JT
    Am J Health Syst Pharm; 2013 Aug; 70(15):1342-6. PubMed ID: 23867491
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Optimizing the delivery and use of a new monoclonal antibody in children with congenital heart disease: a successful provincial respiratory syncytial virus prophylaxis program.
    Warren A; Langley JM; Thomas W; Scott J
    Can J Cardiol; 2007 May; 23(6):463-6. PubMed ID: 17487291
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Comparing First- and Second-year Palivizumab Prophylaxis in Patients With Hemodynamically Significant Congenital Heart Disease in the CARESS Database (2005-2015).
    Li A; Wang DY; Lanctôt KL; Mitchell I; Paes BA;
    Pediatr Infect Dis J; 2017 May; 36(5):445-450. PubMed ID: 28403044
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.